Research location

Beaver

Pennsylvania, United States

Published trials213
Site observations214
Linked trials published213
Page2 / 5
Advertisement

Research activity in Beaver

Pennsylvania, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 213 trials and 214 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Beaver

213 linked trials · page 2 of 5
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 DiabetesNCT03987919 · 2019-07-30 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney DiseaseNCT04026165 · 2019-07-24 · 1 site observation
COMPLETED
EndoPredict® Extended Endocrine Trial (EXET)NCT04016935 · 2019-07-02 · 1 site observation
TERMINATED
A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesNCT03914326 · 2019-06-17 · 1 site observation
COMPLETED
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseaseNCT03819153 · 2019-06-17 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneNCT03954834 · 2019-06-03 · 1 site observation
COMPLETED
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)NCT03971474 · 2019-05-28 · 1 site observation
COMPLETED
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 DiabetesNCT03882970 · 2019-04-01 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskNCT03730662 · 2018-11-20 · 1 site observation
COMPLETED
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes MellitusNCT03586830 · 2018-06-26 · 1 site observation
COMPLETED
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE TrialNCT03371719 · 2018-06-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Efpeglenatide on Cardiovascular OutcomesNCT03496298 · 2018-04-27 · 1 site observation
TERMINATED
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With DocetaxelNCT03419234 · 2018-04-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 DiabetesNCT03495102 · 2018-04-05 · 1 site observation
COMPLETED
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerNCT03414970 · 2018-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskNCT03315143 · 2017-12-19 · 1 site observation
TERMINATED
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboNCT03281954 · 2017-12-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyNCT03332771 · 2017-12-01 · 1 site observation
COMPLETED
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30 · 1 site observation
COMPLETED
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 DiabetesNCT03214380 · 2017-07-14 · 1 site observation
COMPLETED
Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast SurgeryNCT03188393 · 2017-04-13 · 1 site observation
COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes MellitusNCT03086330 · 2017-03-15 · 1 site observation
COMPLETED
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic DrugsNCT03078478 · 2017-03-13 · 1 site observation
COMPLETED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03 · 1 site observation
COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With InsulinNCT03021187 · 2017-02-02 · 1 site observation
COMPLETED
Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNCT02834013 · 2017-01-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 DiabetesNCT02692716 · 2017-01-17 · 1 site observation
COMPLETED
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation
TERMINATED
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin MonotherapyNCT02973100 · 2016-12-01 · 1 site observation
COMPLETED
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesNCT02595905 · 2016-09-15 · 1 site observation
COMPLETED
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerNCT02642042 · 2016-07-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor AgonistNCT02738151 · 2016-05-19 · 1 site observation
COMPLETED
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 DiabetesNCT02730377 · 2016-03-28 · 1 site observation
COMPLETED
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes MellitusNCT02501161 · 2016-01-31 · 1 site observation
COMPLETED
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02785952 · 2015-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT02446132 · 2015-11-13 · 1 site observation
TERMINATED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's TypeNCT02442778 · 2015-11-11 · 1 site observation
COMPLETED
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyNCT02445391 · 2015-10-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney DiseaseNCT02540993 · 2015-09-17 · 1 site observation
COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney DiseaseNCT02545049 · 2015-09-17 · 1 site observation
COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerNCT02488967 · 2015-07-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)NCT02451137 · 2015-06-16 · 1 site observation
COMPLETED
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerNCT02438722 · 2015-05-07 · 1 site observation
COMPLETED
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)NCT02201992 · 2015-03-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)NCT02193282 · 2015-02-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer PatientsNCT02376296 · 2015-02-01 · 1 site observation
COMPLETED
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.